Would the new formulation of metformin, Glucophage XR, be helpful to people with IGT?
The DPP researchers did not use Glucophage XR and therefore do not have any information about its potential value in preventing diabetes. Do the DPP interventions affect the risk of cardiovascular disease, an important cause of mortality in people with type 2 diabetes? DPP researchers are still analyzing the data and performing more studies to determine whether the interventions affected the development of atherosclerosis, which causes cardiovascular disease, or cardiovascular disease itself. These were important secondary outcomes in the study. Are there any plans to get information about the DPP to the public and health care professionals? The American Diabetes Association and NIDDK have a joint committee developing clinical recommendations for health care providers that will provide guidance on how the results of DPP can be applied to individual patients. The results of this work will be published in the next few months. The National Diabetes Education Program (NDEP), a jointly spon
